ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Group 1 - Schubert Jonckheer & Kolbe LLP is investigating potential legal claims related to ImmunityBio, Inc.'s unsuccessful efforts to secure regulatory approval for its product Anktiva, which is intended for bladder cancer treatment [1] - A class action complaint has been filed against ImmunityBio, alleging that the company misled investors about the prospects of obtaining FDA approval for Anktiva by concealing issues related to recordkeeping, quality control, and sanitation at its contract manufacturer [2] - Following the revelation of these issues in May 2023, ImmunityBio's stock experienced a significant decline of 55% [2] Group 2 - The Schubert firm is looking into potential wrongdoing by ImmunityBio's officers and directors in connection with the allegations made in the class action complaint [3] - Current shareholders of ImmunityBio are encouraged to seek additional information regarding their legal rights [3]